Literature DB >> 20954006

Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier.

Corbin Bachmeier1, Michael Mullan, Daniel Paris.   

Abstract

Alzheimer's disease (AD) is characterized by excessive cerebrovascular deposition of the β-amyloid peptide (Aβ). The investigation of Aβ transport across the blood-brain barrier (BBB) has been hindered by inherent limitations in the cellular systems currently used to model the BBB, such as insufficient barrier properties and poor reproducibility. In addition, many of the existing models are not of human or brain origin and are often arduous to establish and maintain. Thus, we characterized an in vitro model of the BBB employing human brain microvascular endothelial cells (HBMEC) and evaluated its utility to investigate Aβ exchange at the blood-brain interface. Our HBMEC model offers an ease of culture compared with primary isolated or coculture BBB models and is more representative of the human brain endothelium than many of the cell lines currently used to study the BBB. In our studies, the HBMEC model exhibited barrier properties comparable to existing BBB models as evidenced by the restricted permeability of a known paracellular marker. In addition, using a simple and rapid fluormetric assay, we showed that antagonism of key Aβ transport proteins significantly altered the bi-directional transcytosis of fluorescein-Aβ (1-42) across the HBMEC model. Moreover, the magnitude of these effects was consistent with reports in the literature using the same ligands in existing in vitro models of the BBB. These studies establish the HBMEC as a representative in vitro model of the BBB and offer a rapid fluorometric method of assessing Aβ exchange between the periphery and the brain.

Entities:  

Year:  2010        PMID: 20954006      PMCID: PMC2995137          DOI: 10.1007/s10616-010-9313-x

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  27 in total

1.  Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model.

Authors:  Maki Ujiie; Dara L Dickstein; Douglas A Carlow; Wilfred A Jefferies
Journal:  Microcirculation       Date:  2003-12       Impact factor: 2.628

2.  Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats.

Authors:  G Jancsó; F Domoki; P Sántha; J Varga; J Fischer; K Orosz; B Penke; A Becskei; M Dux; L Tóth
Journal:  Neurosci Lett       Date:  1998-09-04       Impact factor: 3.046

3.  In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability.

Authors:  N Strazielle; J F Ghersi-Egea; J Ghiso; M P Dehouck; B Frangione; C Patlak; J Fenstermacher; P Gorevic
Journal:  J Neuropathol Exp Neurol       Date:  2000-01       Impact factor: 3.685

4.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

5.  Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.

Authors:  Francisco J Gonzalez-Velasquez; Joseph A Kotarek; Melissa A Moss
Journal:  J Neurochem       Date:  2008-09-16       Impact factor: 5.372

6.  Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.

Authors:  G L Bowman; J A Kaye; M Moore; D Waichunas; N E Carlson; J F Quinn
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

Review 7.  Intracellular amyloid-beta in Alzheimer's disease.

Authors:  Frank M LaFerla; Kim N Green; Salvatore Oddo
Journal:  Nat Rev Neurosci       Date:  2007-07       Impact factor: 34.870

8.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

9.  Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins.

Authors:  Enika Nagababu; Peter V Usatyuk; Divya Enika; Viswanathan Natarajan; Joseph M Rifkind
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Evidence that the Amyloid beta Precursor Protein-intracellular domain lowers the stress threshold of neurons and has a "regulated" transcriptional role.

Authors:  Luca Giliberto; Dawang Zhou; Richard Weldon; Elena Tamagno; Pasquale De Luca; Massimo Tabaton; Luciano D'Adamio
Journal:  Mol Neurodegener       Date:  2008-09-02       Impact factor: 14.195

View more
  14 in total

1.  Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier.

Authors:  Ben Shackleton; Charis Ringland; Laila Abdullah; Michael Mullan; Fiona Crawford; Corbin Bachmeier
Journal:  Mol Neurobiol       Date:  2019-06-18       Impact factor: 5.590

2.  Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Authors:  Daniel Paris; Corbin Bachmeier; Nikunj Patel; Amita Quadros; Claude-Henry Volmar; Vincent Laporte; Jim Ganey; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Fiona Crawford; Michael J Mullan
Journal:  Mol Med       Date:  2010-12-17       Impact factor: 6.354

3.  The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.

Authors:  Daniel Paris; Ghania Ait-Ghezala; Corbin Bachmeier; Gary Laco; David Beaulieu-Abdelahad; Yong Lin; Chao Jin; Fiona Crawford; Michael Mullan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

4.  Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.

Authors:  Corbin Bachmeier; David Beaulieu-Abdelahad; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  J Mol Neurosci       Date:  2012-08-14       Impact factor: 3.444

Review 5.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 6.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

7.  Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier.

Authors:  Brian P Daniels; Lillian Cruz-Orengo; Tracy Jo Pasieka; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; John A Cooper; Tamara L Doering; Robyn S Klein
Journal:  J Neurosci Methods       Date:  2012-10-13       Impact factor: 2.390

8.  Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.

Authors:  Corbin Bachmeier; Ben Shackleton; Joseph Ojo; Daniel Paris; Michael Mullan; Fiona Crawford
Journal:  Neuromolecular Med       Date:  2014-12       Impact factor: 3.843

9.  Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner.

Authors:  Gordon S Lee; Katharina Kappler; Christopher J H Porter; Martin J Scanlon; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2015-08-07       Impact factor: 4.200

10.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.

Authors:  Candice E Van Skike; Jordan B Jahrling; Angela B Olson; Naomi L Sayre; Stacy A Hussong; Zoltan Ungvari; James D Lechleiter; Veronica Galvan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.